The global life sciences hub Switzerland

Thursday, March 18, 2021 @ 12:00 am

The second annual WuXi Healthcare Forum, Partnership for Patients, from March 15 -18 brought together 6,000+ biotech colleagues from around the world who are working to address global healthcare challenges with global solutions.

Check out the recording of the panel Switzerland: A Global Life Sciences Hub in the Heart of Europe, led by the Swiss Biotech Association, showcasing the strengths of the Swiss biotech hub.

Speakers

Session Leader: Michael Altorfer, CEO, Swiss Biotech Association
Ulf Grawunder, CEO, NBE Therapeutics
Chandra Leo, Investment Advisor, HBM Partners
Chris Martin, CEO, Co-Founder & Director, ADC Therapeutics
Alex Mayweg, Managing Director, Versant Ventures
Jordi Montserrat, Co-Founder & Managing Partner, Venturelab

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

LubioScience and IDT launch gene product for biotech applications

LubioScience, Switzerland’s largest R&D reagent platform, has teamed up with Integrated DNA Technologies (IDT) to launch Rapid Genes, a revolutionary product designed to streamline high-throughput workflows. The genes are shipped in as little as five business days, offering speed and precision that will significantly benefit researchers and biotech companies.
September 13, 2024

Bioversys receives USD 6 million from Guangzhou Sino-Israel Bio-Industry Investment Fund

GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study
September 11, 2024

ABCDX: Heart-type fatty acid binding protein as biomarker for Transient Ischemic Attack

ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "Heart-type fatty acid binding protein as a biomarker in transient ischemic attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transi
September 9, 2024

Boehringer Ingelheim and CDR-Life advance treatment for Geographic Atrophy

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II tria
September 5, 2024

HAYA Therapeutics: Collaboration with Eli Lilly to target obesity and related metabolic conditions

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
September 4, 2024